Posted on Nov 27, 2018, 12 a.m.
The novel drug dasotraline has been linked with significant improvement in psychological and behavioral outcomes as compared with placebo in adults with binge eating disorder.
317 patients were included in this double blind randomized trial for 12 weeks with either placebo or flexible dosed dasotraline at 4 mg/day, 6 mg/day, and 8 mg/day. Dasotraline is a dual acting norepinephrine and dopamine reuptake inhibitor.
Results showed the mean drop of binge eating days per week was greater with dasotraline at -3.74 vs -2.75 for placebo. Dasotraline performed better on mean endpoint changes on the Yale Brown Obsessive Compulsive Scale Modified for Binge Eating total scores -17.05 vs -9.88, compulsion subscale score -8.69 vs -5.35, and obsession subscale score -8.32 vs -4.58. The mean endpoint change was greater with dasotraline on the Eating Disorder Examination Brief Version on the global score -0.93 vs -0.43, and weight concern -1.03 vs -0.44.
Dasotraline has also been shown to improve ADHD symptoms in children in a phase 3 trail for up to 24 hours, in a 2 weeks randomized double blind study involving 112 children.
Materials provided by:
Note: Content may be edited for style and length.
Navia B, Hudson JI, McElroy SL, et al. Dasotraline for treatment of adults with binge-eating disorder: effect on behavioral outcomes. Poster presented at Psych Congress 2018: October 25-28, 2018; Orlando, FL. Poster 311.